ME
MENS.US Jyong Biotech Ltd. Ordinary Shares
- Market cap
- USD 134M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is MENS.US undervalued?
Graham numberThe Graham number of Jyong Biotech Ltd. Ordinary Shares cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jyong Biotech Ltd. Ordinary Shares fundamental analysis
No fundamental analysis for Jyong Biotech Ltd. Ordinary Shares yet.
Jyong Biotech Ltd. Ordinary Shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jyong Biotech Ltd. Ordinary Shares
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is…
Full company profileJyong Biotech Ltd. Ordinary Shares financial statements
Jyong Biotech Ltd. Ordinary Shares annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | -121K | -122K | -127K | -120K | -100K |
| Operating Income | -2.45M | -2.40M | -2.83M | -2.80M | -2.06M | -2.61M |
| EBITDA | -2.34M | -3.24M | -5.74M | -3.52M | -1.86M | -2.51M |
| Net Income | -1.92M | -4.20M | -6.63M | -4.40M | -3.02M | -4.67M |
| EPS | -0.03 | -0.06 | -0.09 | -0.06 | -0.04 | -0.06 |
| Balance Sheet | ||||||
| Total Assets | 12.8M | 9.43M | 8.75M | 8.25M | 6.37M | 20.8M |
| Total Liabilities | 32.0M | 32.8M | 38.4M | 42.3M | 42.9M | 45.7M |
| Shareholders' Equity | -19.2M | -23.3M | -29.6M | -34.1M | -36.5M | -24.9M |
| Cash & Short-term Investments | 4.22M | 2.39M | 812K | 177K | 98.0K | 1.18M |
| Total Debt | 13.6M | 11.8M | 14.3M | 16.7M | 18.1M | 18.5M |
| Cash Flow | ||||||
| Operating Cash Flow | -1.09M | -1.98M | -2.97M | -2.60M | -3.62M | -3.04M |
| Capital Expenditure | 88.0K | 137K | 246K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -1.18M | -2.12M | -3.22M | -2.60M | -3.62M | -3.04M |
| Ratios | ||||||
| ROA | -14.9% | -44.5% | -75.8% | -53.3% | -47.4% | -22.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
Jyong Biotech Ltd. Ordinary Shares dividends
Jyong Biotech Ltd. Ordinary Shares has not paid dividends in the last 6 fiscal years.
Who owns Jyong Biotech Ltd. Ordinary Shares
- Insiders 62.20%
- Institutions 0.74%
- Public & others 37.06%
- Shares outstanding 74.2M
- Free float 26.9M
Top funds holding MENS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Biotechnology ETF | 226K | 0.31% | -0.19% | Oct 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 60.0K | 0.08% | +0.21% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 46.7K | 0.06% | 0.00% | Aug 2026 |
| Fidelity Nasdaq Composite ETF | 26.9K | 0.04% | 0.00% | Oct 2026 |
| China Universal NASDAQ Bio-Tch ETF(QDII) | 12.1K | 0.02% | -2.33% | Jun 2026 |
| Invesco Nasdaq Biotechnology ETF | 5.72K | 0.01% | 0.00% | Oct 2026 |
| ProShares Ultra Nasdaq Biotechnology | 3.04K | 0.00% | 0.00% | Oct 2026 |
| GF NASDAQ Bio-Tech Idx QDII USD A | 1.56K | 0.00% | +4.42% | Jun 2026 |
Top institutions holding MENS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 260K | 0.35% | +0.60% | Jun 2026 |
| Geode Capital Management, LLC | 68.9K | 0.09% | +7.24% | Jun 2026 |
| HRT FINANCIAL LLC | 50.4K | 0.07% | +328.51% | Jun 2026 |
| XTX Topco Ltd | 29.1K | 0.04% | 0.00% | Jun 2026 |
| China Universal Asset Mgmt Co.Ltd | 12.1K | 0.02% | -8.15% | Jun 2026 |
| State of Wyoming | 11.2K | 0.02% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 6.11K | 0.01% | -3.00% | Jun 2026 |
| Barclays PLC | 5.93K | 0.01% | +14.30% | Jun 2026 |
| JPMorgan Chase & Co | 5.38K | 0.01% | -5.28% | Jun 2026 |
| UBS Group AG | 4.05K | 0.01% | -89.17% | Jun 2026 |
| Mirae Asset Global Investments (Korea) Co Ltd | 3.40K | 0.00% | -12.19% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 2.71K | 0.00% | +44.07% | Jun 2026 |
| Citigroup Inc | 2.50K | 0.00% | -10.26% | Jun 2026 |
| Tower Research Capital LLC | 1.07K | 0.00% | -90.86% | Jun 2026 |
| Cornerstone Financial Management, LLC | 234.00 | 0.00% | 0.00% | Jun 2026 |
| Bell Investment Advisors, Inc | 206.00 | 0.00% | -56.45% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 9.00 | 0.00% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 0.00 | 0.00% | -100.00% | Jun 2026 |
| JustInvest LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Millennium Management LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Jyong Biotech Ltd. Ordinary Shares company profile
- Company name
- Jyong Biotech Ltd. Ordinary Shares
- Ticker
- MENS.US
- ISIN
- KYG831161065
- Exchange
- USA Stocks
- Listed since
- Jun 17, 2025
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 27
- Fiscal year end
- December
- Address
- No. 95, Xintai 5th Road, New Taipei City, Taiwan, 221
- Phone
- 886 2 2732 5205
- Website
- jyongbio.com
About Jyong Biotech Ltd. Ordinary Shares
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
Jyong Biotech Ltd. Ordinary Shares management
3- Ms. Fu-Feng KuoCEO & Chairwoman of the Board · born 1958
- Ms. Wei ZhangChief Financial Officer · born 1981
- Dr. Fenglin Hsu Ph.D.CTO & Director · born 1949